Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Actin, gamma-enteric smooth muscle (ACTG2)
- Target
- ACTG2
- Molecular classification
- Other, Cytoskeletal protein (actin family member)
01
Overview
Actin, gamma-enteric smooth muscle is a member of the actin family of cytoskeletal proteins. Encoded by the ACTG2 gene, it is specifically expressed in smooth muscle cells of the gastrointestinal and urinary tracts. This actin isoform is essential for the contractile function of these muscles, thereby regulating bladder emptying and intestinal motility. Pathogenic missense mutations in ACTG2 are linked to disorders such as megacystis-microcolon-intestinal hypoperistalsis syndrome and chronic intestinal pseudo-obstruction, diseases characterized by severe impairment of smooth muscle contraction. While critical to cellular structure and function, ACTG2 is not a therapeutic target in the conventional sense, due to the essential nature and structural ubiquity of actins in all cells.
- Other names
- Gamma-2-actinSmooth muscle gamma-actinAlpha-actin-3ACTA3ACTL3ACTSGActin, gamma 2, smooth muscleactin gamma
02
Mechanism of action
Not applicable; no known drugs target ACTG2 directly.
03
Biological functions
Smooth muscle contraction (urinary and intestinal tracts)Cell motilityMaintenance of the cytoskeletonMuscle fiber tension and movement
04
Disease associations
Megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS)Intestinal pseudo-obstructionOther visceral myopathies
05
Safety considerations
No direct therapeutic targeting; thus, safety concern relates primarily to genetic diseases stemming from loss or alteration of function (e.g., severe visceral myopathy, disorders of intestinal/bladder motility)Mutations can lead to impaired peristalsis, urine retention, and intestinal blockage mimicking obstruction
06
Biomarkers
Mutations in ACTG2 serve as genetic biomarkers for MMIHS and related digestive/urinary tract motility disorders
Beyond the preview
Go deeper on Actin, gamma-enteric smooth muscle (ACTG2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Actin, gamma-enteric smooth muscle (ACTG2).